MOLOGEN AG: Collaboration with licensing partner ONCOLOGIE gains momentum - EQS
20-Apr-2018 12:51
============
DGAP-News: MOLOGEN AG / Key word(s): Alliance
MOLOGEN AG: Collaboration with licensing partner ONCOLOGIE gains momentum
20.04.2018 / 12:51
The issuer is solely responsible for the content of this announcement.
--------------------------------------------------------------------------
PRESS RELEASE N 9 / 2018 of 20/04/2018
MOLOGEN AG: Collaboration with licensing partner ONCOLOGIE gains momentum
Berlin, 20 April 2018 - The biopharmaceutical company MOLOGEN AG announced
today that the collaboration with ONCOLOGIE, agreed on in February 2018,
is making good progress. The collaboration includes a license agreement
for the development, manufacturing and commercialization for MOLOGEN's
lead compound lefitolimod in East Asian markets and a global
co-development leveraging novel biomarker know-how from ONCOLOGIE. In this
context lefitolimod is initially planned to be developed in oncological
indications with high unmet medical need.
"We are excited about the forthcoming collaboration with ONCOLOGIE: Under
the partnership we will implement ONCOLOGIE's innovative biomarker-driven
development strategy for our TLR9 agonist lefitolimod to unleash its full
potential in different oncological indications and support our development
efforts in China and also globally", said Dr Mariola Soehngen, Chief
Executive Officer of MOLOGEN.
"ONCOLOGIE's novel biomarker-driven approach allows us to conduct targeted
basket or umbrella trials with lefitolimod. Therefore we will be able to
unleash lefitolimod's potential as single agent and especially in
combination with other immunotherapeutics and develop tailor-made
therapies against different kinds of tumors", said Dr Matthias Baumann,
Chief Medical Officer of MOLOGEN.
"With our operations now firmly established in the U.S. and China,
ONCOLOGIE is excited to collaborate globally with MOLOGEN and leverage the
unmet needs as well as the new opportunities available for clinical
development in China. We believe that we have synergy with MOLOGEN that
will help lefitolimod reach its full potential as a best-in-class cancer
therapeutic," said Dr Laura Benjamin, Chief Executive Officer of
ONCOLOGIE.
Within the framework of the contract MOLOGEN has received an initial
payment of EUR 3 million and a EUR 2 million equity investment by
ONCOLOGIE is to follow within the next 12 months after the signing of the
contract. Besides the initial payment and the equity investment, the
parties agreed on further development and commercialisation milestones.
They are due upon reaching predefined development steps as well as market
approval. In addition, commercial milestones are defined which are due
upon reaching certain sales thresholds. The total payments can amount to
above EUR 100 million and will be paid over several years. Additionally,
MOLOGEN will receive low double digit royalties on sales. MOLOGEN and
ONCOLOGIE will share the economic returns from global joint development
pursuant to both parties' contributions.
All costs relating to development, registration, marketing and
commercialization of lefitolimod in the territory are to be covered by
ONCOLOGIE.
ONCOLOGIE Ltd.
ONCOLOGIE is an oncology therapeutics company committed to delivering
improved outcomes for cancer patients by leveraging innovative compounds
and biomarker-driven clinical development. The current pipeline is focused
on mid-stage clinical programs that modify the tumor microenvironment.
ONCOLOGIE has operations established in Boston, Massachusetts, US, and
Shanghai, China. ONCOLOGIE is working with global partners to acquire and
develop innovative drugs for cancer patients around the world.
1 www.oncologie.international.
MOLOGEN AG
MOLOGEN AG is a biopharmaceutical company and a pioneer in the field of
immunotherapy on account of its unique active agents and technologies.
Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for
the treatment of infectious diseases.
The focus of the development work is on the product family of DNA-based
TLR9 agonists. This includes the lead product candidate lefitolimod and
the next-generation molecule family EnanDIM^(R).
The immunotherapeutic agent lefitolimod is the company's lead product
candidate and is currently being investigated in a pivotal trial. It is
regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod
triggers a broad and strong activation of the immune system. On account of
this mode of action, lefitolimod could potentially be used in various
indications. Lefitolimod is currently being developed within the framework
of a pivotal study for first line maintenance therapy for colorectal
cancer. Key data of the phase II IMPULSE study in small cell lung cancer
have been announced in April 2017, and the final analysis in the first
quarter 2018 confirmed the data. Furthermore, data from the extension
phase of the TEACH study in HIV have also been published in 2017. In
addition, lefitolimod is currently being investigated in a phase I
combination study with the checkpoint inhibitor ipilimumab (Yervoy^(R)) in
various cancer indications. Along with various checkpoint inhibitors,
lefitolimod, which is being investigated as part of a phase III clinical
trial currently, is one of the few near-to-market product candidates in
the field of immuno-oncology.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat
diseases for which there is a great medical demand in particular.
MOLOGEN AG is a publicly listed company, headquartered in Berlin. The
shares (ISIN DE0006637200, SIN 663720) are listed in the Prime Standard of
the German Stock Exchange.
2 www.mologen.com
Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com
Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.
--------------------------------------------------------------------------
20.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
--------------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: presse@mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Regulated Market in Frankfurt (Prime Standard); Regulated
Listed: Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
677065 20.04.2018
3 fncls.ssp?
AI
